Front-Line Treatment with Second-Generation Tyrosine Kinase Inhibitors Following By Allo-Transplantation Benefits Patients with Better Survival Inph-Positive Acute Lymphoblastic Leukemia

被引：0
|
作者：
Yu, Pan
Chen, Fang
Xu, Dan
Yin, Changxin
Liu, Qifa
Sun, Jing
Fan, Zhiping
Wang, Qiang
Liu Xiaoli
Jiang, Qianli
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4522
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Real-World Use of First and Second Generation Tyrosine Kinase Inhibitors Pre- and Post-Hematopoietic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    Takiar, Radhika
    Perissinotti, Anthony J.
    Marini, Bernard L.
    Benitez-Colon, Lydia
    Burke, Patrick W.
    Crouch, Ashley
    Bixby, Dale
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S190 - S190
  • [42] Impact of Posttransplant Tyrosine Kinase Inhibitors Administration on Long Term Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in ph-positive Acute Lymphoblastic Leukemia Patients
    Afanaseva, Kseniia
    Morozova, Elena
    Pirogova, Olga
    Vlasova, Yulia
    Smirnova, Anna
    Bondarenko, Sergey
    Moiseev, Ivan
    Afanasyev, Boris
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 203 - 204
  • [43] Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia
    Brissot, Eolia
    Labopin, Myriam
    Beckers, Marielle M.
    Socie, Gerard
    Rambaldi, Alessandro
    Volin, Liisa
    Finke, Juergen
    Lenhoff, Stig
    Kroeger, Nicolaus
    Ossenkoppele, Gert J.
    Craddock, Charles F.
    Yakoub-Agha, Ibrahim
    Gurman, Gunhan
    Russell, Nigel H.
    Aljurf, Mahmoud
    Potter, Michael N.
    Nagler, Armon
    Ottmann, Oliver
    Cornelissen, Jan J.
    Esteve, Jordi
    Mohty, Mohamad
    HAEMATOLOGICA, 2015, 100 (03) : 392 - 399
  • [44] Early Maintenance with Tyrosine Kinase Inhibitors Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Improves Survival in Ph plus Acute Lymphoblastic Leukemia (ALL) Patients
    Gowda, Lohith
    Alijadayeh, Majdi
    Marin, David Costa
    Ledesma, Celina
    Rondon, Gabriela
    Popat, Uday
    Alousi, Amin M.
    Oran, Betul
    Shah, Mithun Vinod
    Ahmed, Sairah
    Kanagal-Shamanna, Rashmi
    Ciurea, Stefan O.
    Shpall, Elizabeth J.
    Luthra, Raja
    Hosing, Chitra
    Qazilbash, Muzaffar H.
    Rezvani, Katy
    Jabbour, Elias J.
    Patel, Keyur P.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Champlin, Richard E.
    Kebriaei, Partow
    BLOOD, 2017, 130
  • [45] Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Daver, Naval
    Thomas, Deborah
    Ravandi, Farhad
    Cortes, Jorge
    Garris, Rebecca
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Kadia, Tapan
    Rytting, Michael
    Konopleva, Marina
    Kantarjian, Hagop
    O'Brien, Susan
    HAEMATOLOGICA, 2015, 100 (05) : 653 - 661
  • [46] BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy
    Riva, G.
    Luppi, M.
    Quadrelli, C.
    Barozzi, P.
    Basso, S.
    Vallerini, D.
    Zanetti, E.
    Morselli, M.
    Forghieri, F.
    Maccaferri, M.
    Paolini, A.
    Del Giovane, C.
    D'Amico, R.
    Marasca, R.
    Narni, F.
    Iacobucci, I.
    Martinelli, G.
    Baccarani, M.
    Comoli, P.
    Potenza, L.
    BLOOD CANCER JOURNAL, 2011, 1 : e30 - e30
  • [47] BCR–ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy
    G Riva
    M Luppi
    C Quadrelli
    P Barozzi
    S Basso
    D Vallerini
    E Zanetti
    M Morselli
    F Forghieri
    M Maccaferri
    A Paolini
    C Del Giovane
    R D'Amico
    R Marasca
    F Narni
    I Iacobucci
    G Martinelli
    M Baccarani
    P Comoli
    L Potenza
    Blood Cancer Journal, 2011, 1 : e30 - e30
  • [48] Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes
    Kebriaei, Partow
    Saliba, Rima
    Rondon, Gabriela
    Chiattone, Alexandre
    Luthra, Rajyalakshmi
    Anderlini, Paolo
    Andersson, Borje
    Shpall, Elizabeth
    Popat, Uday
    Jones, Roy
    Worth, Laura
    Ravandi, Farhad
    Thomas, Deborah
    O'Brien, Susan
    Kantarjian, Hagop
    de Lima, Marcos
    Giralt, Sergio
    Champlin, Richard
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (04) : 584 - 592
  • [49] Blinatumomab plus Tyrosine Kinase Inhibitors in the Treatment of Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Patients - Clinical Efficacy and Peripheral Blood Lymphocytes Subpopulations Kinetics
    Sokolov, Andrey N.
    Parovichnikova, Elena N.
    Troitskaya, Vera V.
    Galtseva, Irina V.
    Davidova, Julia O.
    Kapranov, Nikolai M.
    Obukhova, Tatiana N.
    Savchenko, Valeri G.
    BLOOD, 2016, 128 (22)
  • [50] The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure
    Jabbour, Elias
    Kantarjian, Hagop
    Ghanem, Hady
    O'Brien, Susan
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    Cardenas, Marylou
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (03): : 302 - 306
12345